Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

| More on:
A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week.

Three ASX shares that brokers have named as buys this week are listed below. Here's why their analysts are feeling bullish on them right now:

Gentrack Group Ltd (ASX: GTK)

According to a note out of Bell Potter, its analysts have retained their buy rating on this utilities software company's shares with a trimmed price target of $13.20. This follows the release of a half year result this week that was below expectations. Bell Potter notes that project revenues within utilities dragged slightly against a strong prior period and the phasing of contract wins. Nevertheless, it remains positive on the future and is bullish on Gentrack's ability to maintain customer win momentum. It expects this to support high NRR revenues, which will flow onto ARR. The Gentrack share price is trading at $10.57 on Wednesday afternoon.

ResMed Inc. (ASX: RMD)

A note out of Goldman Sachs reveals that its analysts have retained their conviction buy rating and $49.30 price target on this sleep disorder treatment company's shares. This follows news that Apnimed has had success with its phase 3 trial of a sleep apnoea pill. Goldman Sachs isn't concerned and feels that the share price weakness caused by the news has been an overreaction. It believes that Apnimed's AD109's pill is unlikely to displace CPAP as first line therapy in treating OSA. Particularly given that its initial target opportunity are patients who have refused or have failed CPAP. In light of this, Goldman Sachs remains as bullish as ever on ResMed and its long term zoutlook. The ResMed share price is fetching $38.80 at the time of writing.

TechnologyOne Ltd (ASX: TNE)

Analysts at UBS have retained their buy rating on this enterprise software company's shares with an improved price target of $42.20. According to the note, the broker was impressed with TechnologyOne's half year results. It highlights that annual recurring revenue grew strongly and was in line with its expectations. Whereas its profits were comfortably ahead of its estimates for the half. Combined with its strong net revenue retention rate and ultra low churn levels, it believes the result supports its bullish view on the long term growth outlook of the company. The Technology One share price is trading at $38.46 this afternoon.

Motley Fool contributor James Mickleboro has positions in ResMed and Technology One. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Gentrack Group, Goldman Sachs Group, ResMed, and Technology One. The Motley Fool Australia has positions in and has recommended Gentrack Group and ResMed. The Motley Fool Australia has recommended Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Two workers at an oil rig discuss operations.
Broker Notes

Should you buy Santos, Beach Energy or Woodside shares? Here's Macquarie's top pick

Macquarie has released its new share price expectations for Santos, Beach Energy and Woodside shares.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

person holding hat
Broker Notes

3 ASX 200 large-cap shares just re-rated by analysts

We reveal the latest views on an ASX 200 large-cap miner, retailer, and consumer staples leader.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Down 80% in 2025: Is it time to buy this beaten down ASX stock?

Let's see what Bell Potter is saying about this stock after its heavy decline.

Read more »

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Broker Notes

NextDC shares jump 11% on major OpenAI deal

This data centre operator will be home to the AI giant in Australia.

Read more »

A large clear wine glass on the left of the image filled with fifty dollar notes on a timber table with a wine cellar or cabinet with bottles in the background.
Broker Notes

Macquarie names 3 top dividend-paying ASX 200 shares to buy today

Macquarie expects these three dividend paying ASX 200 shares to outperform in 2026. Let’s see why.

Read more »

Confident male executive dressed in a dark blue suit leans against a doorway with his arms crossed in the corporate office
Broker Notes

Broker reveals ratings on 4 ASX 200 sector leaders

Prefer ASX 200 large-cap stocks? Here are some new ratings and price targets for four sector leaders.

Read more »

A young boy points and smiles as he eats fried chicken.
Broker Notes

Why brokers are bullish on this rapidly-growing ASX 200 share

This business is delivering tasty earnings growth…

Read more »